Document is current
Any future updates will be listed below
-
Authors
Pepin, Mark E https://orcid.org/0000-0003-0114-560X
Gong, Xuemin https://orcid.org/0009-0006-3657-7954
Schulze, Almut
Backs, Johannes https://orcid.org/0000-0002-2322-2699
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (INST 35/1699-1)
Alexander von Humboldt-Stiftung
Deutsche Zentrum Fur Herz-Kreislauf-Forschung (81X3500135)
- License Information
-
More Information
Article History
Received: 6 August 2025
Revised: 4 October 2025
Accepted: 9 October 2025
First Online: 11 December 2025
Disclosure and competing interests statement
: JB holds a patent on “ABHD5 and partial HDAC4 fragments and variants as a therapeutic approach for the treatment of cardiovascular diseases.” and is Founder of REVIER Therapeutics that develops first in class IIa HDAC inhibitors for the therapy of cardiometabolic disease. AS has no conflicts of interest to disclose. MEP serves as a clinical consultant for Suki AI.
